News | EP Lab | February 02, 2021

Patient Data From Several Cardiac Devices Streamlined Into One Platform With New Cloud-based Software

Optimize EP launches CaRM cardiac device data management platform to automates workflow processes and enhances data algorithms

The Optimize EP CaRM software integrates data from several EP devices a patients may use and aggregate it into one location.

The Optimize EP CaRM software integrates data from several EP devices a patients may use and aggregate it into one location. 

February 2, 2021 – Optimize EP, a digital health company focused on transforming cardiac care by improving the current state of cardiac data management, recently emerged from stealth mode to announce the launch of CaRM, the company’s unique cloud-based software that streamlines patient data from multiple electrophysiology (EP) cardiac devices onto one accessible and easy-to-use platform. 

Founded by Maninder Bedi, M.D., who also serves as the company’s chief medical officer, Optimize EP incorporates both enterprise performance management (EPM) and electronic medical record (EMR) systems effortlessly into the CaRM software. It features data algorithms designed specifically to help physicians, clinical teams and administrators overcome the challenges associated with codifying and simplifying the immense amount of remote monitoring data transmitted each day so care teams can deliver improved and differentiated patient care. 

“Remote monitoring has the potential to dramatically improve patient care, but the reality of managing cardiac device data is daunting; it can be chaotic and time-consuming,” Bedi said, who is a practicing electrophysiologist with Regional Cardiac Arrhythmia in Steubenville, Ohio. “CaRM can streamline data from both implantable and external devices and features a number of automated processes that simplify day-to-day workflow, making it possible for clinical teams to devote more time to treating more patients.” 

CaRM integrates a variety of hospital and clinic billing software programs, ensuring the accuracy of reimbursement codes and the essential capture of associated revenue. The platform can be customized to create unique alerts and notifications, increasing the functionality and simplicity of the interface. CaRM also syncs directly with the FDA’s product recall page, automatically and immediately alerting physicians to any FDA recall announcements impacting their patients’ devices, giving them the opportunity to adjust treatment strategies and alter care quickly. 

“On the clinical side of things, CaRM can make patient care easier, but for hospitals and clinics, it can also strengthen their operational margins,” said Ravi Kartan, president and CEO of Optimize EP. “CaRM is an invaluable tool for those EPs and cardiologists who own their practices and rely on intuitive technologies like ours to keep things up and running. It’s a practical digital tool for sustainability and profitability.” 

CaRM is commercially available in the United States.

Founded in 2018, Optimize EP is a digital health company focused on transforming cardiology care by improving cardiac data management to create sustainable, profitable practices that deliver optimal patient care. CaRM, the company’s proprietary software developed by a practicing electrophysiologist, is a cloud-based platform that improves efficiency and streamlines the clinical and administrative operations necessary for efficient cardiac device remote monitoring, reimbursement and billing.

For more information: https://www.optimizeep.com

Related Content

Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Detecting heart disease with OCT imaging of the eye.Getty Images

Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Getty Images
 

News | Cardiac Diagnostics | March 08, 2021
March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potent
Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia.

Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG strip on a smartphone. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia. 

News | Cardiac Diagnostics | March 03, 2021
March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management s
A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images Health disparities in cardiovascular disease.

A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images

News | Cardiac Diagnostics | February 02, 2021
February 2, 2021 — A new study has found in the U.S.
A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

News | Cardiac Diagnostics | January 06, 2021
January 6, 2021 — Smoking traditional cigarettes in addition to using e-cigarettes results in harmful health effects
The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en
heart disease image
News | Cardiac Diagnostics | December 18, 2019
December 18, 2019 — In their latest report, “...
FDA Warns Troponin Tests Impacted by Biotin Dietary Supplement
Feature | Cardiac Diagnostics | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — The U.S.